0 152

Cited 1 times in

Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer

DC FieldValueLanguage
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.date.accessioned2018-08-28T17:20:33Z-
dc.date.available2018-08-28T17:20:33Z-
dc.date.issued2018-
dc.identifier.issn1743-7555-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162495-
dc.description.abstractAIM: We describe a subgroup analysis assessing the efficacy and safety of ramucirumab monotherapy in East Asian (EA) patients from the REGARD trial. METHODS: Patients with advanced gastric or gastroesophageal junction adenocarcinoma with progressive disease were randomized 2:1 to receive ramucirumab (8 mg/kg) plus best supportive care (BSC) or placebo plus BSC every 2 weeks. Post hoc subset analyses were performed on the EA and non-EA intention-to-treat populations. RESULTS: Of 355 intention-to-treat patients, 26 patients from EA were randomized to ramucirumab (n = 18) or placebo (n = 8). Median overall survival was 6.5 months in the ramucirumab arm and 4.8 months in the placebo arm (hazard ratio [HR] 0.69; 95% confidence interval [CI], 0.27-1.82) for EA patients, and 5.2 months in the ramucirumab arm and 3.8 months in the placebo arm (HR 0.78; 95% CI, 0.60-1.02) for non-EA patients. The rate of disease control was numerically higher in ramucirumab patients versus placebo; 61% versus 38% respectively for EA patients, and 48% versus 22% for non-EA patients. The incidence of grade >/=3 treatment emergent adverse events was higher in the ramucirumab arm compared to placebo (39% vs 13%). CONCLUSION: Despite limitations, this subgroup analysis suggests that ramucirumab monotherapy improves efficacy outcomes with a tolerable safety profile in EA patients with previously treated advanced gastric cancer.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Pub. Asia-
dc.relation.isPartOfASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleSubgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorVictor C Kok-
dc.contributor.googleauthorRebecca Cheng-
dc.contributor.googleauthorYanzhi Hsu-
dc.contributor.googleauthorMauro Orlando-
dc.contributor.googleauthorCharles Fuchs-
dc.contributor.googleauthorJae Yong Cho-
dc.identifier.doi10.1111/ajco.12829-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.relation.journalcodeJ00257-
dc.identifier.eissn1743-7563-
dc.identifier.pmid29318751-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/abs/10.1111/ajco.12829-
dc.subject.keywordAsia-
dc.subject.keywordgastric cancer-
dc.subject.keywordgastrointestinal neoplasms-
dc.subject.keywordramucirumab-
dc.subject.keywordvascular endothelial growth factor receptor-2-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameCho, Jae Yong-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorCho, Jae Yong-
dc.citation.volume14-
dc.citation.number3-
dc.citation.startPage204-
dc.citation.endPage209-
dc.identifier.bibliographicCitationASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.14(3) : 204-209, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.